<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11110-2012041 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Characterization of broadly neutralizing antibodies for rational antibody-based HIV-1 vaccine design</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">An HIV vaccin would be an effective way to eradicate HIV. The induction of broadly HIV-1 neutralizing antibodies (bNAbs) by vaccination is challenging, but understanding how a subset of HIV-infected individuals (elite neutralizers) develops bNAbs may guide immunization strategies. The aim of the project is to define the characteristics of elite neutralizing antibody responses as well as the characteristics of Env required to elicit broadly neutralizing antibodies to create novel Env trimer vaccines.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">An HIV vaccin would be an effective way to eradicate HIV. To date there is no effective HIV vaccin available. The HIV antibody response in almost 30% of those people living with HIV is much more resistant than in other people living with HIV. This group&#x2019;s antibodies are more effective in identifying and disabling HIV, but still not adequately enough to eradicate the virus. AMC researchers are studying this efficient and resistant antibody response, which may just provide the key to an HIV vaccine.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The proposed project aims to: 
This project has 3 aims:
1. To determine the evolution of the neutralizing B cell response in elite neutralizers.
2. To determine the Env epitopes targeted by elite neutralizers.
3. To determine the Env characteristics required to re-elicit broadly neutralizing
antibodies.
This will help in future design of a vaccin.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientists</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2012-11-30" type="1"></activity-date>
  <activity-date iso-date="2015-11-30" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Characterization of broadly neutralizing antibodies for rational antibody-based HIV-1 vaccine design STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2012-11-30"></period-start>
   <period-end iso-date="2015-11-30"></period-end>
   <value currency="EUR" value-date="2012-11-30">245882</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">196700</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012041, CG656003</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">196700</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012041, CG656003</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-09-13"></transaction-date>
   <value currency="EUR" value-date="2016-09-13">42388</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012041, CG656003</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-09-14"></transaction-date>
   <value currency="EUR" value-date="2016-09-14">42388</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2012041, CG656003</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
